Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Acrocephalosyndactylia 6Cholangiocarcinoma 4Neoplasm Metastasis 3Myeloproliferative Disorders 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Stomach Neoplasms 1Solid Tumor 1Recurrence 1Oligodendroglioma 1Neoplasms, Unknown Primary 1Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Eosinophilia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

tanespimycin 2pembrolizumab 2parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2zanidatamab 1tislelizumab 1spartalizumab 1sitravatinib 1repaglinide 1pemigatinib 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1drospirenone 1cabiralizumab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1HMPL-013 1Gemcitabine 1Ethinyl Estradiol 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignancies × pemigatinib × Clear all
NCT04949191 2024-09-19

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Incyte Corporation

Phase 2 Terminated
10 enrolled 9 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡